Suven gets two patents from China and Russia

City-based biopharmaceutical company Suven Life Sciences announced on Tuesday that two product patents were granted in China and Russia to two of their new chemical entities (NCEs) for treatment of neurodegenerative diseases. These are valid until 2023 and 2024 respectively. These are being developed as therapeutic agents for treatment of cognitive impairment associated with Alzheimer’s disease, attention deficient hyperactivity disorder, Huntington’s, Parkinson and schizophrenia. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, said its chief executive officer Venkat Jasti. The Company has six therapeutic drug candidates currently in pre-clinical stage, according to a filing on the Bombay Stock Exchange. Its stock is traded at Rs 30, up 5.44 per cent from the previous close of Rs 30.35 on the BSE.